Convalescent Plasma Therapy for COVID-19: Current Status and Future Directions

Jayanth Seshan; Surya K. Dube; Vanitha Rajagopalan; Pragyan S. Panda; Girija P. Rath

doi:10.1055/s-0040-1716594

Journal of Neuroanaesthesiology and Critical Care, Inhaltsverzeichnis

CC BY-NC-ND 4.0 · J Neuroanaesth Crit Care 2020; 7(03): 140-147
DOI: 10.1055/s-0040-1716594

Review Article

Convalescent Plasma Therapy for COVID-19: Current Status and Future Directions

Jayanth Seshan

¹Department of Neuroanaesthesiology and Critical Care, Neurosciences Center, All India Institute of Medical Sciences, New Delhi, India

,

Surya K. Dube

¹Department of Neuroanaesthesiology and Critical Care, Neurosciences Center, All India Institute of Medical Sciences, New Delhi, India

,

Vanitha Rajagopalan

¹Department of Neuroanaesthesiology and Critical Care, Neurosciences Center, All India Institute of Medical Sciences, New Delhi, India

,

Pragyan S. Panda

²Department of Microbiology, Janakpuri Super Speciality Hospital Society, Janakpuri, New Delhi, India

,

Girija P. Rath

¹Department of Neuroanaesthesiology and Critical Care, Neurosciences Center, All India Institute of Medical Sciences, New Delhi, India

› Institutsangaben

Abstract

The ongoing pandemic of coronavirus disease 2019 (COVID-19) has triggered a global health crisis probably due to a lack of a reliable cure till date. Several clinical trials are ongoing, but initial results have not been overly promising. Convalescent plasma (CP), which refers to plasma collected from individuals recovered from an illness and developed antibodies against the pathogen, is also being proposed as a therapeutic option for COVID-19 treatment in severe cases to achieve short-term immunity against the virus. Use of CP is not new, and it has been used in various outbreaks over the past century, ranging from the Spanish influenza outbreak in 1918 to the recent Middle East respiratory syndrome (MERS). However, data available on its use in COVID-19 patients is limited. Use of CP so far is restricted to a “rescue therapy” and needs further trials to assess its possible use in other situations (prevention, postexposure prophylaxis) and patient populations (considering age and comorbid illnesses). In this review, we will try to summarize the current status of use of CP for COVID-19 and ongoing trials in India and elsewhere and will discuss the possible avenues for its use in future.

Keywords

convalescent plasma - coronavirus - COVID-19 - immunotherapy - SARS-CoV-2

Volltext

Referenzen

References
1 Huang C, Wang Y, Li X. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395 (10223) 497-506
2 Vanamoorthy P, Singh GP, Bidkar PU. et al. The Neurocritical Care Society of India (NCSI) and the Indian Society of Neuroanaesthesiology and Critical Care (ISNACC) Joint Position Statement and Advisory on the Practice of Neurocritical Care during the COVID-19 Pandemic. J Neuroanaesth Crit Care 2020; 2: 49-114
3 Li L, Zhang W, Hu Y. et al. Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: a randomized clinical trial. JAMA 2020; 324 (05) 1-11
4 Ko JH, Seok H, Cho SY. et al. Challenges of convalescent plasma infusion therapy in Middle East respiratory coronavirus infection: a single centre experience. Antivir Ther 2018; 23 (07) 617-622
5 Cheng Y, Wong R, Soo YO. et al. Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur J Clin Microbiol Infect Dis 2005; 24 (01) 44-46
6 Hung IF, To KK, Lee CK. et al. Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection. Clin Infect Dis 2011; 52 (04) 447-456
7 Zhou B, Zhong N, Guan Y. Treatment with convalescent plasma for influenza A (H5N1) infection. N Engl J Med 2007; 357 (14) 1450-1451
8 Sahr F, Ansumana R, Massaquoi TA. et al. Evaluation of convalescent whole blood for treating Ebola Virus Disease in Freetown, Sierra Leone. J Infect 2017; 74 (03) 302-309
9 Ruggiero HA, Pérez Isquierdo F, Milani HA. et al. Treatment of Argentine hemorrhagic fever with convalescent’s plasma. 4433 cases [in French]. Presse Med 1986; 15 (45) 2239-2242
10 Bloch EM, Shoham S, Casadevall A. et al. Deployment of convalescent plasma for the prevention and treatment of COVID-19. J Clin Invest 2020; 130 (06) 2757-2765
11 Duan K, Liu B, Li C. et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc Natl Acad Sci U S A 2020; 117 (17) 9490-9496
12 U.S. Food and Drug Administration. Recommendations for Investigational COVID-19 Convalescent Plasma. Available at: https://www.fda.gov/vaccines-blood-biologics/investigational-new-drug-ind-or-device-exemption-ide-process-cber/recommendations-investigational-covid-19-convalescent-plasma. Accessed April 29, 2020
13 World Health Organization. Blood donor selection: guidelines on assessing donor suitability for blood donation. Available at: https://apps.who.int/iris/handle/10665/76724. Accessed June 5, 2020
14 Marano G, Vaglio S, Pupella S. et al. Convalescent plasma: new evidence for an old therapeutic tool?. Blood Transfus 2016; 14 (02) 152-157
15 Williams AE. FDA Considerations Regarding Frequent Plasma Collection Procedures. Available at: https://www.ihn-org.com/wp-content/uploads/2019/08/4-Williams FreqPlasma-2-21-131.pdf. Accessed June 5, 2020
16 U.S. Food and Drug Administration. Compliance Policy Guide (CPG): CPG Sec. 252.110 Volume Limits for Automated Collection of Source Plasma (Obsolete, Withdrawn on 11/28/2017). Available at: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-252110-volume-limits-automated-collection-source-plasma-obsolete-withdrawn-11282017. Accessed April 27, 2020
17 Wong HK, Lee CK, Hung IFN. et al. Practical limitations of convalescent plasma collection: a case scenario in pandemic preparation for influenza A (H1N1) infection. Transfus (Paris) 2010; 50 (09) 1967-1971
18 Arabi YM, Hajeer AH, Luke T. et al. Feasibility of using convalescent plasma immunotherapy for MERS-CoV infection, Saudi Arabia. Emerg Infect Dis 2016; 22 (09) 1554-1561
19 Jh K, Ma MHS, Ge P. et al. Serologic responses of 42 MERS-coronavirus-infected patients according to the disease severity. Diagn Microbiol Infect Dis 2017; 89 (02) 106-111
20 Katzelnick LC, Gresh L, Halloran ME. et al. Antibody-dependent enhancement of severe dengue disease in humans. Science 2017; 358 (6365) 929-932
21 Shen C, Wang Z, Zhao F. et al. Treatment of 5 critically ill patients with COVID-19 with convalescent plasma. JAMA 2020; 323 (16) 1582-1589
22 van Griensven J, Edwards T, de Lamballerie X. et al. Evaluation of convalescent plasma for Ebola virus disease in Guinea. N Engl J Med 2016; 374 (01) 33-42
23 World Health Organization. Use of convalescent whole blood or plasma collected from patients recovered from Ebola virus disease. Available at: https://www.who.int/csr/resources/publications/ebola/convalescent-treatment/en/. Accessed June 4, 2020
24 Kong L. Severe acute respiratory syndrome (SARS). Transfus Apher Sci. 2003; 29 (01) 101
25 Johns Hopkins Medicine. Coronavirus COVID-19. Available at: https://www.hopkinsguides.com/hopkins/.//view/Johns_Hopkins_ABX_Guide/540747/all/Coronavirus_COVID_19__SARS_CoV_2?refer=true. Accessed April 27, 2020
26 Soo YO, Cheng Y, Wong R. et al. Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS patients. Clin Microbiol Infect 2004; 10 (07) 676-678
27 Casadevall A, Joyner MJ, Pirofski LA. A randomized trial of convalescent plasma for COVID-19-potentially hopeful signals. JAMA 2020;
28 Mair-Jenkins J, Saavedra-Campos M, Baillie JK. et al. The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis. J Infect Dis 2015; 211 (01) 80-90
29 Chan KK, Lee KL, Lam PKN, Law KI, Joynt GM, Yan WW. Hong Kong’s experience on the use of extracorporeal membrane oxygenation for the treatment of influenza A (H1N1). Hong Kong Med J 2010; 16 (06) 447-454
30 Chen N, Zhou M, Dong X. et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020; 395 (10223) 507-513
31 Hellstern P, Muntean W, Schramm W, Seifried E, Solheim BG. Practical guidelines for the clinical use of plasma. Thromb Res 2002; 107: S53-S57
32 Luke TC, Kilbane EM, Jackson JL, Hoffman SL. Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment?. Ann Intern Med 2006; 145 (08) 599-609
33 Mourya DT, Yadav PD, Majumdar TD, Chauhan DS, Katoch VM. Establishment of Biosafety Level-3 (BSL-3) laboratory: important criteria to consider while designing, constructing, commissioning & operating the facility in Indian setting. Indian J Med Res 2014; 140 (02) 171-183
34 Valk SJ, Piechotta V, Chai KL. et al. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a rapid review. Cochrane Database Syst Rev 2020; 5 (05) CD013600
35 CTRI. A Phase II, Open Label, Randomized Controlled Trial to Assess the Safety and Efficacy of Convalescent Plasma to Limit COVID-19 Associated Complications in Moderate Disease. Available at: http://ctri.nic.in/Clinicaltrials/showallp.php?mid1=43149&EncHid=&userName=convalescent%20plasma. Accessed May 25, 2020
36 Search Result, Clinical Trials Registry - India (CTRI) [Internet]. [cited 2020 May 25]. Available at: http://ctri.nic.in/Clinicaltrials/pubview2.php. Accessed May 25, 2020
37 National COVID-19 Convalescent Plasma Project. Component 3: Clinical Trials. Available at: https://ccpp19.org/healthcare_providers/component_3/index.html. Accessed May 25, 2020
38 Zhang B, Liu S, Tan T. et al. Treatment with convalescent plasma for critically Ill patients with SARS-CoV-2 infection. Chest 2020; 158 (01) e9-e13
39 Yeh KM, Chiueh TS, Siu LK. et al. Experience of using convalescent plasma for severe acute respiratory syndrome among healthcare workers in a Taiwan hospital. J Antimicrob Chemother 2005; 56 (05) 919-922